“…157,161 Recently, several reports have demonstrated the relevance of sPRR in the pathogenesis of hypertension. Mice with the treatment of S1P inhibitor PF429242 162 and mutations of the cleavage site of PRR 115,116 exhibited lower BP in response to AngII infusion (300 ng•kg −1 •min −1 for 14 days, 116,162 400 ng•kg −1 •day −1 for 14 days 115 ), accompanied by attenuated AngII-induced vasoconstriction and acetylcholine as well as the activation of intrarenal RAS and ENaC, both of all were partially reversed by F I G U R E 3 Hypertensive actions of the brain (A) and renal (B) (Pro)renin receptor (PRR) in response to multiple stimulus (e.g., Prorenin infusion, AngII infusion, DOCA/salt treatment, Fructose/salt intake, etc.). ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AngI, angiotensin I; AngII, angiotensin II; AT1R, type 1 AngII receptor; ENaC, epithelial sodium channel; Nedd4-2, neural precursor cell expressed by developmentally downregulated gene 4-2; NOX 4 , NADPH oxidase 4; pERK1/2, phosphorylated extracellular signal-regulated kinase 1/2; ROS, reactive oxygen species; SGK-1, serum-and-glucocorticoid-inducible kinase 1 exogenous mouse recombinant sPRR infusion.…”